// App-Quantinova.ai

AB0362 : TIGHT CONTROL OF DISEASE ACTIVITY BY CONVENTIONAL DMARDS COULD MINIMIZE THE USE OF BIOLOGICAL THERAPIES IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: DATA FROM AN EARLY ARTHRITIS CLINIC IN HONG KONG

Researchers

Presenter

  • C.H. To

Principal Investigators

  • L.Y. Ho

  • K.L. Yu

  • K.L. Chan

  • P.T. Chan

  • C.C. Mok

Medical Centers

  • Department of Nuclear Medicine, Queen Mary Hospital, Hong Kong, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Hydroxychloroquine

  • sulphasalazine

  • Methotrexate

  • HWA-486

  • Adalimumab

  • Infliximab

  • Etanercept

  • CHS-0214

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved